Focusing on hepatitis B and central nervous system diseases, experts are calling for the elimination of prejudice and the face of the disease

GlaxoSmithKline brought classic core prescription drugs to the appointment to protect the health of Chinese people

SHANGHAI, Nov.
6, 2022 /PRNewswire/ -- Professor Xu Jie, Director of the Department of Infectious Diseases, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, and Professor Ding Jing, Deputy Director of the Department of Neurology, Zhongshan Hospital, Fudan University, at the GlaxoSmithKline (GSK) booth at the 5th China International Import Expo (CIIE).
Professor Ji Jianlin, Director of the Department of Psychological Medicine, Zhongshan Hospital affiliated to Fudan University, Ms.
Huang Jingxuan, Head of GSK China's Core Prescription Business Unit, and Mr.
Yang Haosheng, Head of HIV and Product Portfolio Strategic Medical Affairs, GSK China He was invited to conduct in-depth discussions on the current status of disease prevention and control and disease management in China for hepatitis B, epilepsy, depression, bipolar disorder and other central nervous system diseases, aiming to enhance public awareness of diseases, eliminate prejudice, bridge the distance between patients and the public, and jointly contribute to a healthy China
with the help of the platform and wide influence of the Expo.

China is still a large country with hepatitis B, and experts stress the importance of early screening and active treatment

In recent years, with the efforts of all parties, China's hepatitis B prevention and control has achieved remarkable results, but due to the huge base, China is still a large country of
hepatitis B.
At present, because the symptoms of hepatitis B in the early stage are not obvious, it is easy to be ignored by patients, resulting in delayed medical treatment, and gradually progressing to cirrhosis and even liver cancer, which seriously threatens the survival of
patients.
Professor Xu Jie emphasized that early screening and active treatment can effectively reduce new chronic infections and reduce mortality
.

Screening is crucial
for the diagnosis and prevention of hepatitis B in China, to delay or prevent the progress of hepatitis B histological progress, and to improve the coverage of hepatitis B treatment.
Experts remind: For the general population, especially high-risk groups of chronic hepatitis B virus (HBV), such as human immunodeficiency virus (HIV) infected people, men who have sex with men, intravenous drug addicts, sexual partners and family contacts of HBV-infected patients, pregnant women, and people receiving immunosuppressants or antitumor drugs and anti-HCV drugs, they should take the initiative to go to medical institutions for hepatitis B surface antigen (HBsAg) screening, so that they should be screened ^[1].

At present, the mainstream treatment of chronic hepatitis B (hereinafter referred to as "chronic hepatitis B") is oral antiviral drugs ^[2].

In recent years, evidence-based medicine has confirmed that receiving antiviral therapy can effectively inhibit HBV replication, reduce liver inflammatory necrosis, effectively block and reverse liver fibrosis and even early cirrhosis, thereby reducing complications related to cirrhosis and reducing the mortality rate
of hepatocellular carcinoma (HCC) and liver disease.

In addition, Professor Xu Jie called on the public to view hepatitis B correctly and eliminate disease discrimination
.
She pointed out that hepatitis B is a preventable and treatable disease, and vaccination is the most cost-effective way to
prevent hepatitis B.
By insisting on taking medication and standardizing treatment, hepatitis B patients can also return to normal life
.

Medication as prescribed by a doctor is an effective way to control epilepsy, and experts are calling for the elimination of disease bias

In China, epilepsy is the second most common disease
in neurology after stroke.
In recent years, the incidence of epilepsy in China has shown an upward trend, among which the incidence of children and adolescents is higher
.
In fact, epilepsy is not only a medical issue, but also an important public health and social issue
.
The negative impact of seizures on patients' physical and mental health, quality of life, and long-term heavy economic burden can cause patients to have more serious psychological disorders
.
Professor Ding Jing emphasized that epilepsy is not an incurable disease, and scientific and standardized diagnosis and treatment is the key to
coping with epilepsy.
The Global Epilepsy Report published by the World Health Organization in 2019 also pointed out that 25% of epilepsy can be prevented early, and 70% of epilepsy patients can achieve seizure-free
with effective and low-cost drugs.

In addition, there are still misunderstandings and even discrimination
against people with epilepsy among the public and society.
Professor Ding Jing called for humanistic care to be placed in the same important position as treatment, eliminate prejudice, help the public establish a correct understanding of epilepsy, and let patients receive timely treatment and social support, so as to enhance their confidence
in overcoming the disease.

Face up to emotional problems, seek timely treatment, and standardize treatment to help patients return to normal life

With the accelerated pace of modern life and the increased burden of life and work, many people suffer from emotional disorders such as anxiety, depression, and bipolar disorder
.
Because of this, in recent years, the government has paid more and more attention to the mental health
of the people.
The report of the 20th National Congress of the Communist Party of China clearly pointed out: attach importance to mental health and mental health
.

Emotional illness has a variety of hazards, seriously affecting the life and health of patients, and even endangering life
.
In bipolar disorder, for example, at least one fifth of patients have committed suicide and cognitive impairment
may occur due to the pronevolence of neurons in certain areas of the brain for a long time.
In addition, the incidence of diabetes may increase two- to four-fold, and patients with bipolar disorder may lose 10 to 12 years of life without proper treatment [3][4].

At present, drugs are the main means of treating anxiety, depression, bipolar disorder and other emotional diseases, and patients can be effectively controlled
on the basis of maintaining drug treatment and psychotherapy.
Professor Ji Jianlin pointed out that regular medication can reduce recurrence and help control the disease
.
Patients should distinguish between normal mood swings and mood diseases, seek timely treatment, and actively fight the disease
.

Under the epidemic, every ordinary individual should learn to objectively assess their own pressure and "be the first responsible person for their own health"
.
Professor Ji Jianlin reminded the public that they should be vigilant about emotional, physiological and physical reactions, and when the emotional disorder lasts for too long, they should consider the possibility of emotional illness and seek medical attention
in time.

Experts appeal: everyone should be treated gently, eliminate stigma, face up to the disease, do not shy away from seeking medical treatment, and find it as soon as possible, in order to regain the original life
from its hands as soon as possible.

GSK brought classic core prescription drugs to the Expo again to protect the health of Chinese people

This year marks the fifth consecutive year that GSK China has participated in CIIE, and it is also the "China debut"
of GSK's new image after the transformation.
This year, the GSK Expo booth once again showcased its innovative R&D achievements in the central nervous system and hepatitis B fields, as well as its efforts
to support the prevention and treatment of diseases in China.
Over the years, GSK has always been "caring for patients", bringing many innovative products to Chinese patients, covering epilepsy, anxiety and depression, bipolar disorder, Parkinson's disease, chronic hepatitis B and other disease areas, actively responding to the urgent health needs
of Chinese patients.

GSK has been deeply involved in hepatitis B and antiviral therapy in China for more than 20 years, and has been committed to providing effective treatment options for patients, benefiting more than 1 million hepatitis B patients in China
.
Mr.
Yang Haosheng, Head of HIV and Product Portfolio Strategy at GSK China, said: "We have always put patient needs as our top priority and are committed to continuous innovation
for a future without hepatitis B.
From GSK's development and production of China's first chronic hepatitis B antiviral drug, to 2014, Veride (tenofovir disoproxil fumarate tablets) was launched in
China.
In order to benefit more patients, we continue to develop new drugs and expand the boundaries of
liver disease treatment.
GSK antisense oligonucleotide therapy Bepirovirsen (GSK836) is expected to bring "functional cure" to Chinese patients with chronic hepatitis B, at present, the Drug Evaluation Center of the China Food and Drug Administration has accepted the application for the phase III clinical study of the drug, once the conditions are mature, we will actively take action to introduce it into China to benefit more Chinese patients
faster and better.
"

As a global pioneer in the field of central nervous system, GSK has continuously expanded the boundaries of classic medicine since the first drug for depression was introduced in 1995, looking for new "keys"
.
Taking ribitone (lamotrigine tablets) as an example, it was approved for clinical use in the treatment of
epilepsy in 1996.
In the long-term clinical process, GSK found the needs of some special groups of the elderly, children, and patients with dysphagia, and launched a dispersible tablet form in 2018 to improve the accuracy of titration dose and the convenience of taking medication from the perspective of process improvement.
In 2021, it was approved for the new indication of bipolar disorder, increasing the treatment options
of current Chinese doctors.

At the same time, GSK also fully supports the prevention and treatment of diseases in China, helping to improve disease awareness and standardize diagnosis and treatment
.
"China is the world's second largest healthcare market, and GSK is deeply engaged in chronic disease management and neurological diseases, continuously improving product accessibility and affordability, expanding regional and population coverage, expanding health influence in China, and enhancing people's sense
of health attainment," said Huang Jingxuan, Head of GSK China's Core Prescription Business Unit 。 At the same time, we will work together to explore innovative medical solutions and build a health layout of "integrated medical prevention and prevention", so that innovative achievements and high-quality medical resources can benefit more Chinese patients and the public
in a more timely manner.
”